Evidence map›Paper›PMID 42477734›Full record

ArticleJournal of biomedical science2026

Emetine dihydrochloride inhibits Chikungunya virus nsP2 helicase and shows robust antiviral activity in cells and mice.

Anshula Sharma, Chandru Subramani, K A Shouri, Ghanshyam Sharma, Brohmomoy Basu, Abhay Deep Pandey, Archana Rout, Devendra Sharma, Deepti Jain, Sudhanshu Vrati

Abstract read
In one paragraph

Article in Journal of biomedical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anshula SharmaRegional Centre for Biotechnology, Faridabad, 121 001, India.
Chandru SubramaniRegional Centre for Biotechnology, Faridabad, 121 001, India.
K A ShouriRegional Centre for Biotechnology, Faridabad, 121 001, India.
Ghanshyam SharmaRegional Centre for Biotechnology, Faridabad, 121 001, India.
Brohmomoy BasuRegional Centre for Biotechnology, Faridabad, 121 001, India.
Abhay Deep PandeyRegional Centre for Biotechnology, Faridabad, 121 001, India.
Archana RoutRegional Centre for Biotechnology, Faridabad, 121 001, India.
Devendra SharmaRegional Centre for Biotechnology, Faridabad, 121 001, India.
Deepti JainRegional Centre for Biotechnology, Faridabad, 121 001, India.
Sudhanshu VratiRegional Centre for Biotechnology, Faridabad, 121 001, India. vrati@rcb.res.in.

Funding

Department of Biotechnology (DBT), Govt. of India BT/BI/14/042/2017 and BT/MED/32/11/2019Science and Engineering Research Board JCB/2021/000015
6 · The paper itself

Abstract

backgroundChikungunya virus (CHIKV), a mosquito-borne alphavirus, causes frequent global epidemics of chikungunya fever, characterized by severe joint pain and debilitating arthritis. With no specific antiviral therapies available, these outbreaks pose a major public health challenge, particularly in tropical regions. There is thus urgent need to develop novel antivirals. Drug repurposing is an attractive strategy to identify potential antivirals targeting CHIKV replication.

methodsThe Spectrum collection of approved drugs was screened using high-content cell imaging to identify potential CHIKV replication inhibitors. Efficacy of these CHIKV inhibitors was evaluated in a C57BL/6 mouse model of chikungunya disease, monitoring viremia and clinical symptoms like joint swelling. The CHIKV inhibitor's effect on virus uptake, replication, RNA synthesis, and protein production was studied in ERMS cells. In silico molecular docking was used to study the inhibitor's binding to the CHIKV proteins. Binding was validated in vitro using microscale thermophoresis and isothermal titration calorimetry. CHIKV helicase, protease, and ATPase activities were measured in the presence of emetine dihydrochloride (ED) to determine its mechanism of action.

resultsOut of the four CHIKV inhibitors identified by high content screening, ED potently inhibited CHIKV replication in the mouse model, yielding significantly lower viremia levels. Notably, CHIKV-infected mice treated with ED showed no clinical symptoms of joint swelling. In ERMS cells, ED blocked CHIKV uptake and early replication by suppressing viral RNA synthesis, which in turn prevented viral protein production. Computational modelling predicted ED's binding around the RNA-binding site of the CHIKV nsP2 helicase domain. In vitro validation confirmed dose-dependent ED binding with CHIKV nsP2. ED specifically inhibited helicase unwinding in a concentration-dependent manner without affecting ATPase or protease activity.

conclusionsThis study demonstrates that ED inhibits CHIKV replication in cultured cells and a mouse model of infection through binding to CHIKV nsP2 and inhibition of its helicase activity. While this is a promising virus-targeted mechanism of ED's antiviral action, additional host-directed mechanisms warrant further investigation.

Indexed as

Antiviral AgentsChikungunya FeverChikungunya virusEmetineRNA HelicasesViral Nonstructural ProteinsVirus ReplicationAnimalsHumansMiceMice, Inbred C57BLAntiviral AgentsEmetineRNA HelicasesViral Nonstructural ProteinsMicroscale thermophoresisMouse modelRNA replication

Identifiers

PMID42477734
PMCPMC13386891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.